RESULTS OF THE IV PHASE OF THE OPEN CLINICAL TRIAL ON EFFICACY AND SAFETY OF ABATACEPT USAGE IN CHILDREN AND ADOLESCENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS IN RUSSIA
Aim: to assess efficacy and safety of abatacept usage in children and adolescents with polyarticular juvenile idiopathic arthritis without systemic manifestations. Patients and methods: 15 patients aged 13 (11; 14,5) years old were included into the study; the mean duration of disease course was 4 (...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2013-07-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/307 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849249919799394304 |
|---|---|
| author | E. I. Alexeeva S. I. Valieva T. M. Bzarova R. V. Denisova K. B. Isaeva T. V. Sleptsova E. V. Mitenko N, I, Taibulatov |
| author_facet | E. I. Alexeeva S. I. Valieva T. M. Bzarova R. V. Denisova K. B. Isaeva T. V. Sleptsova E. V. Mitenko N, I, Taibulatov |
| author_sort | E. I. Alexeeva |
| collection | DOAJ |
| description | Aim: to assess efficacy and safety of abatacept usage in children and adolescents with polyarticular juvenile idiopathic arthritis without systemic manifestations. Patients and methods: 15 patients aged 13 (11; 14,5) years old were included into the study; the mean duration of disease course was 4 (3; 5) years. The disease was diagnosed based on the ILAR criteria. All the patients were performed routine clinical and laboratory examination. Efficacy of treatment was assessed according to the pediatric criteria for improvement of the American College of Rheumatology (ACRpedi). Target characteristics of treatment efficacy were: the number of patients with 30/50/70/90% improvement according to the ACRpedi criteria during first 4 months from the therapy administration, and then – every 2 months; percentage of non-active stage and remission achievement. Results: in 4 months after beginning of treatment improvement according to the ACRpedi 30/50 criteria was observed in 60/30% of patients; in 6 months according to the ACRpedi 30/50/70 criteria — in 80/40/40%, respectively; in 12 months according to the ACRpedi 70 criteria — in 80% of patients. Non-active stage of disease in 6 and 12 months was confirmed in 6/15 (30%) and 10/15 (60%) of patients, respectively. Remission was confirmed in 10/15 (60%) of children in 12 months of therapy. Side effects were observed in 6/15 (40%) of children and were mild. Three patients had relapses of Herpes labialis infection, 3 other had acute respiratory tract infections. Conclusions: abatacept is effective for treatment of polyarticular juvenile idiopathic arthritis, resistant to steroids, methotrexate and combined immunosuppressive treatment. |
| format | Article |
| id | doaj-art-2b09cd89b20541fe9a5a3033c346a537 |
| institution | Kabale University |
| issn | 1682-5527 1682-5535 |
| language | English |
| publishDate | 2013-07-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj-art-2b09cd89b20541fe9a5a3033c346a5372025-08-20T03:57:26Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352013-07-01124547210.15690/vsp.v12i4.733307RESULTS OF THE IV PHASE OF THE OPEN CLINICAL TRIAL ON EFFICACY AND SAFETY OF ABATACEPT USAGE IN CHILDREN AND ADOLESCENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS IN RUSSIAE. I. Alexeeva0S. I. Valieva1T. M. Bzarova2R. V. Denisova3K. B. Isaeva4T. V. Sleptsova5E. V. Mitenko6N, I, Taibulatov7Scientific Centre of Children Health of RAMS; I.M. Sechenov First Moscow Medical State University,Scientific Centre of Children Health of RAMS, MoscowScientific Centre of Children Health of RAMS, MoscowScientific Centre of Children Health of RAMS, MoscowScientific Centre of Children Health of RAMS, MoscowScientific Centre of Children Health of RAMS, MoscowScientific Centre of Children Health of RAMS, MoscowScientific Centre of Children Health of RAMS, MoscowAim: to assess efficacy and safety of abatacept usage in children and adolescents with polyarticular juvenile idiopathic arthritis without systemic manifestations. Patients and methods: 15 patients aged 13 (11; 14,5) years old were included into the study; the mean duration of disease course was 4 (3; 5) years. The disease was diagnosed based on the ILAR criteria. All the patients were performed routine clinical and laboratory examination. Efficacy of treatment was assessed according to the pediatric criteria for improvement of the American College of Rheumatology (ACRpedi). Target characteristics of treatment efficacy were: the number of patients with 30/50/70/90% improvement according to the ACRpedi criteria during first 4 months from the therapy administration, and then – every 2 months; percentage of non-active stage and remission achievement. Results: in 4 months after beginning of treatment improvement according to the ACRpedi 30/50 criteria was observed in 60/30% of patients; in 6 months according to the ACRpedi 30/50/70 criteria — in 80/40/40%, respectively; in 12 months according to the ACRpedi 70 criteria — in 80% of patients. Non-active stage of disease in 6 and 12 months was confirmed in 6/15 (30%) and 10/15 (60%) of patients, respectively. Remission was confirmed in 10/15 (60%) of children in 12 months of therapy. Side effects were observed in 6/15 (40%) of children and were mild. Three patients had relapses of Herpes labialis infection, 3 other had acute respiratory tract infections. Conclusions: abatacept is effective for treatment of polyarticular juvenile idiopathic arthritis, resistant to steroids, methotrexate and combined immunosuppressive treatment.https://vsp.spr-journal.ru/jour/article/view/307polyarticular juvenile idiopathic arthritisabatacepttreatment |
| spellingShingle | E. I. Alexeeva S. I. Valieva T. M. Bzarova R. V. Denisova K. B. Isaeva T. V. Sleptsova E. V. Mitenko N, I, Taibulatov RESULTS OF THE IV PHASE OF THE OPEN CLINICAL TRIAL ON EFFICACY AND SAFETY OF ABATACEPT USAGE IN CHILDREN AND ADOLESCENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS IN RUSSIA Вопросы современной педиатрии polyarticular juvenile idiopathic arthritis abatacept treatment |
| title | RESULTS OF THE IV PHASE OF THE OPEN CLINICAL TRIAL ON EFFICACY AND SAFETY OF ABATACEPT USAGE IN CHILDREN AND ADOLESCENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS IN RUSSIA |
| title_full | RESULTS OF THE IV PHASE OF THE OPEN CLINICAL TRIAL ON EFFICACY AND SAFETY OF ABATACEPT USAGE IN CHILDREN AND ADOLESCENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS IN RUSSIA |
| title_fullStr | RESULTS OF THE IV PHASE OF THE OPEN CLINICAL TRIAL ON EFFICACY AND SAFETY OF ABATACEPT USAGE IN CHILDREN AND ADOLESCENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS IN RUSSIA |
| title_full_unstemmed | RESULTS OF THE IV PHASE OF THE OPEN CLINICAL TRIAL ON EFFICACY AND SAFETY OF ABATACEPT USAGE IN CHILDREN AND ADOLESCENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS IN RUSSIA |
| title_short | RESULTS OF THE IV PHASE OF THE OPEN CLINICAL TRIAL ON EFFICACY AND SAFETY OF ABATACEPT USAGE IN CHILDREN AND ADOLESCENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS IN RUSSIA |
| title_sort | results of the iv phase of the open clinical trial on efficacy and safety of abatacept usage in children and adolescents with polyarticular juvenile idiopathic arthritis without systemic manifestations in russia |
| topic | polyarticular juvenile idiopathic arthritis abatacept treatment |
| url | https://vsp.spr-journal.ru/jour/article/view/307 |
| work_keys_str_mv | AT eialexeeva resultsoftheivphaseoftheopenclinicaltrialonefficacyandsafetyofabataceptusageinchildrenandadolescentswithpolyarticularjuvenileidiopathicarthritiswithoutsystemicmanifestationsinrussia AT sivalieva resultsoftheivphaseoftheopenclinicaltrialonefficacyandsafetyofabataceptusageinchildrenandadolescentswithpolyarticularjuvenileidiopathicarthritiswithoutsystemicmanifestationsinrussia AT tmbzarova resultsoftheivphaseoftheopenclinicaltrialonefficacyandsafetyofabataceptusageinchildrenandadolescentswithpolyarticularjuvenileidiopathicarthritiswithoutsystemicmanifestationsinrussia AT rvdenisova resultsoftheivphaseoftheopenclinicaltrialonefficacyandsafetyofabataceptusageinchildrenandadolescentswithpolyarticularjuvenileidiopathicarthritiswithoutsystemicmanifestationsinrussia AT kbisaeva resultsoftheivphaseoftheopenclinicaltrialonefficacyandsafetyofabataceptusageinchildrenandadolescentswithpolyarticularjuvenileidiopathicarthritiswithoutsystemicmanifestationsinrussia AT tvsleptsova resultsoftheivphaseoftheopenclinicaltrialonefficacyandsafetyofabataceptusageinchildrenandadolescentswithpolyarticularjuvenileidiopathicarthritiswithoutsystemicmanifestationsinrussia AT evmitenko resultsoftheivphaseoftheopenclinicaltrialonefficacyandsafetyofabataceptusageinchildrenandadolescentswithpolyarticularjuvenileidiopathicarthritiswithoutsystemicmanifestationsinrussia AT nitaibulatov resultsoftheivphaseoftheopenclinicaltrialonefficacyandsafetyofabataceptusageinchildrenandadolescentswithpolyarticularjuvenileidiopathicarthritiswithoutsystemicmanifestationsinrussia |